ORPHA:353334
Congenital retinal arteriovenous communication
Also known as: Congenital arteriovenous anastomoses of the retina · Congenital arteriovenous communication of the retina · Congenital retinal arteriovenous anastomoses
Publications
97
52.7th percentile
Trials
0
Interventional, condition-specific
Researchers
453
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare neurovascular characterized by a unilateral, direct communication between the arterial and venous system in the retina via abnormal, enlarged vessels, but without interposed capillaries. The inferotemporal vasculature is most commonly affected. Patients may be asymptomatic or present with variable degrees of visual loss. Local vascular complications include vascular occlusions or retinal or vitreous hemorrhages. The anomaly may occur in isolation or as part of Wyburn-Mason syndrome, in which intracranial (usually ipsilateral) arteriovenous malformations are present.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018145
- UMLS:C0521570
Additional Mondo synonyms (3)
congenital arteriovenous anastomoses of the retina · congenital arteriovenous communication of the retina · congenital retinal arteriovenous anastomoses
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
97 matched papers (48 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
97
97 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
97 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
48 in the last 10 years · high confidence · 52.7th percentile (publications denominator)
Phrase hits: 97 · MeSH hits: 0
Who's working on it?
453
Distinct author names in 97 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Xu Y3 papers · 2024
Women's Hospital, School of Medicine Zhejiang University, Hangzhou, China.
Papers in Europe PMC - 02Arthur HM2 papers · 2018
Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom.
Papers in Europe PMC - 03Hiraoka M2 papers · 2010
Department of Ophthalmology, Nippon Medical School, Tokyo, Japan. mikihira@nms.ac.jp
Papers in Europe PMC - 04Ikeda T2 papers · 2015
Department of Ophthalmology, Osaka Medical College, Takatsuki City, Japan.
Papers in Europe PMC - 05Johnson RN2 papers · 2017Papers in Europe PMC
- 06Liu W2 papers · 2024
Department of Ophthalmology, Queen's University, Kingston, Ontario.
Papers in Europe PMC - 07McDonald HR2 papers · 2017Papers in Europe PMC
- 08Rao VR2 papers · 2011
Department of Radiodiagnosis and Imaging, Kasturba Hospital, Manipal, India.
Papers in Europe PMC - 09Schmidt D2 papers · 2010
University Freiburg, Augenklinik, Killianstr. 5, 79106 Freiburg, Germany. Dieter.Schmidt@uniklinik-freiburg.de
Papers in Europe PMC - 10Schumacher M2 papers · 2010Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Congenital retinal arteriovenous communication" OR "Congenital arteriovenous anastomoses of the retina" OR "Congenital arteriovenous anastomoses of retina" OR "Congenital arteriovenous communication of the retina" OR "Congenital arteriovenous communication of retina" OR "Congenital retinal arteriovenous anastomoses"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Congenital retinal arteriovenous communication" OR "Congenital arteriovenous anastomoses of the retina" OR "Congenital arteriovenous anastomoses of retina" OR "Congenital arteriovenous communication of the retina" OR "Congenital arteriovenous communication of retina" OR "Congenital retinal arteriovenous anastomoses"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T14:26:36.826Z